Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Lululemon Athletica Inc (LULU) vs Merck & Co., Inc. (MRK) Price & Performance

Lululemon Athletica IncTrade
Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Lululemon Athletica Inc vs Merck & Co., Inc. — how do they compare? Lululemon Athletica Inc trades at $121.26 (market cap $14.26B), while Merck & Co., Inc. trades at $133.16 (market cap $327.94B). The key difference: Merck & Co., Inc. is far larger — about 23× Lululemon Athletica Inc's market cap, and Merck & Co., Inc. pays a 2.56% dividend while Lululemon Athletica Inc pays none. Which is the better fit depends on your goals.

LULUMRK
Market Cap
$14.26B$327.94B
Sector
Consumer CyclicalHealth
52-Week High
$215.88$132.93
52-Week Low
$105.43$77.60
Enterprise Value
$14.89B$374.70B
Dividend Yield
2.56%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Lululemon Athletica Inc

Lululemon stock trades at $120.88, down 5.41% amid broader market weakness in the premium apparel sector. The company maintains strong fundamentals with a P/E of 10.17, net income margin of 13.03%, and consistent earnings beats. Technical indicators show a bullish moving average trend despite overbought RSI readings, with key resistance near $129.

Investment outlook remains positive given undervaluation metrics and international growth potential, though risks include U.S. demand softness and competitive pressures. Analyst consensus targets $129.29 with 41% buy ratings, suggesting moderate upside from current levels.

Merck & Co., Inc.

Merck (MRK) trades at $130.45, down 0.34% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, net income was $18.25B, and the P/E ratio stands at 104.34. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives.

Outlook: Merck's acquisition strategy and consistent dividend payments ($0.85 per share) support a positive view, with analyst consensus price target at $140.58. Risks include high valuation multiples and competitive pressures in pharmaceuticals. Institutional holdings show increased interest, but investors should monitor integration of acquisitions and patent expirations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Lululemon Athletica Inc

Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.

Read more on LULU

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK